Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Drudge

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Journal of Comparative Effectiveness Research|February 23, 2021
Efficacy classification of modern therapies in multiple sclerosisImtiaz A Samjoo, Evelyn Worthington, Christopher Drudge, et al.
Journal of Comparative Effectiveness Research|May 5, 2025
Network connectivity, between-study heterogeneity and timepoint challenges in generalized myasthenia gravis: a feasibility assessment of indirect treatment comparisonsNils Erik Gilhus, Saiju Jacob, Mahmoud Hashim, et al.
Journal of Comparative Effectiveness Research|June 2, 2023
Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysisImtiaz A Samjoo, Christopher Drudge, Sarah Walsh, et al.
Multiple Sclerosis and Related Disorders|July 16, 2022
Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosisImtiaz A Samjoo, Luisa Klotz, Gavin Giovannoni, et al.
Advances in Therapy|March 12, 2026
Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia GravisSaiju Jacob, Mahmoud Hashim, Brian Hutton, et al.
Therapeutic Advances in Neurological Disorders|March 25, 2024
Comparative efficacy of ofatumumab <i>versus</i> oral therapies for relapsing multiple sclerosis patients using propensity score analyses and simulated treatment comparisonsNicholas Riley, Christopher Drudge, Morag Nelson, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Journal of Comparative Effectiveness Research|February 23, 2021
Efficacy classification of modern therapies in multiple sclerosisImtiaz A Samjoo, Evelyn Worthington, Christopher Drudge, et al.
Journal of Comparative Effectiveness Research|May 5, 2025
Network connectivity, between-study heterogeneity and timepoint challenges in generalized myasthenia gravis: a feasibility assessment of indirect treatment comparisonsNils Erik Gilhus, Saiju Jacob, Mahmoud Hashim, et al.
Journal of Comparative Effectiveness Research|June 2, 2023
Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysisImtiaz A Samjoo, Christopher Drudge, Sarah Walsh, et al.
Multiple Sclerosis and Related Disorders|July 16, 2022
Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosisImtiaz A Samjoo, Luisa Klotz, Gavin Giovannoni, et al.
Advances in Therapy|March 12, 2026
Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia GravisSaiju Jacob, Mahmoud Hashim, Brian Hutton, et al.
Therapeutic Advances in Neurological Disorders|March 25, 2024
Comparative efficacy of ofatumumab <i>versus</i> oral therapies for relapsing multiple sclerosis patients using propensity score analyses and simulated treatment comparisonsNicholas Riley, Christopher Drudge, Morag Nelson, et al.
Pageof 2